Plasma-Derived Exosomal Survivin, a Plausible Biomarker for Early Detection of Prostate Cancer

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Khan, Salma ^a   Jutzy, Jessica M S ^a   Valenzuela, Malyn May A ^a   Turay, David ^a   Aspe, Jonathan R ^a   Ashok, Arjun ^a   Mirshahidi, Saied ^a   Mercola, Dan ^c   Lilly, Michael B ^b,d   Wall, Nathan R ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; SURVIVIN;

ARTICLE; CANCER RECURRENCE; CANCER RESISTANCE; CARCINOGENESIS; CELL LEVEL; CONTROLLED STUDY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; ULTRACENTRIFUGATION; WESTERN BLOTTING;

CASE-CONTROL STUDIES; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; EXOSOMES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; NEOPLASM GRADING; NEOPLASM PROTEINS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867602816     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046737     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
3. Lu S, Liu M, Epner DE, Tsai MJ, (1999) Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 13: 376-384.
4. Klein EA, Kupelian PA, (2003) Localised prostate cancer: radiation or surgery? Urol Clin North Am 30: 315-330.
5. Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, et al. (2011) Tumor markers in prostate cancer I: blood-based markers. Acta Oncol 50 Suppl 1: 61-75.
6. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, et al. (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169: 517-523.
7. Bjartell A, Montironi R, Berney DM, Egevad L, (2011) Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncol 50 Suppl 1: 76-84.
8. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, et al. (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294: 433-439.
9. Chang RT, Kirby R, Challacombe BJ, (2012) Is there a link between BPH and prostate cancer? Practitioner 256: 13-16, 12.
10. Guo Z, Dai B, Jiang T, Xu K, Xie Y, et al. (2006) Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10: 309-319.
11. Zhang M, Latham DE, Delaney MA, Chakravarti A, (2005) Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24: 2474-2482.
12. Li Y, Che M, Bhagat S, Ellis K, Kucuk O, et al. (2004) Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. Neoplasia 6: 354-363.
13. Denmeade SR, (1996) Apoptotic pathways in normal prostate and prostate cancer. Prostate 1: 120-125.
14. Howell SB, (2000) Resistance to apoptosis in prostate cancer cells. Mol Urol 4: 225-229.
15. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, et al. (1996) Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148: 1567-1576.
16. Altieri DC, (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22: 8581-8589.
17. Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S, et al. (2004) Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol 171: 1855-1860.
18. Krajewska M, Krajewski S, Banares S, Huang X, Turner B, et al. (2003) Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 9: 4914-4925.
19. Koike H, Sekine Y, Kamiya M, Nakazato H, Suzuki K, (2008) Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer. Urology 72: 1229-1233.
20. Shariat SF, Lothan Y, Saboorian H, Khoddami SM, Roehrborn CG, et al. (2004) Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 100: 751-757.
21. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, et al. (2007) YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 67: 8014-8021.
22. Shen J, Liu J, Long Y, Miao Y, Su M, et al. (2009) Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity. Acta Biochim Biophys Sin (Shanghai) 41: 223-230.
23. Khan S, Aspe JR, Asumen MG, Almaguel F, Odumosu O, et al. (2009) Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. Brit J Cancer 100: 1073-1086.
24. Khan S, Jutzy JMS, Aspe JR, McGregor DW, Neidigh JW, et al. (2011) Survivin is released from cancer cells via exosomes. Apoptosis 16: 1-12.
25. Duijvesz D, Luider T, Bangma CH, Jenster G, (2011) Exosomes as biomarker treasure chests for prostate cancer. Eur Urol 59: 823-831.
26. Fine SW, Epstein JI, (2008) A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score. J Urol 179: 1335-1338 discussion 1338-1339.
27. Mikolajczyk SD, Song Y, Wong JR, Matson RS, Rittenhouse HG, (2004) Are multiple markers the future of prostate cancer diagnostics? Clin Biochem 37: 519-528.
28. Fradet Y, (2009) Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. Curr Opin Urol 19: 243-246.
29. Fiorentino M, Capizzi E, Loda M, (2010) Blood and tissue biomarkers in prostate cancer: state of the art. Urol Clin North Am 37: 131-141 Table of Contents.
30. Ploussard G, de la Taille A, (2010) Urine biomarkers in prostate cancer. Nat Rev Urol 7: 101-109.
31. Mitchell PJ, Welton J, Staffurth J, Court J, Mason MD, et al. (2009) Can urinary exosomes act as treatment response markers in prostate cancer? J Transl Med 7: 4.
32. Koumangoye RB, Sakwe AM, Goodwin JS, Patel T, Ochieng J, (2011) Detachment of breast tumor cells induces rapid secretion of exosomes which subsequently mediate cellular adhesion and spreading. PLoS One 6: e24234.
33. Johnstone RM, (2006) Exosomes biological significance: A concise review. Blood Cells Mol Dis 36: 315-321.
34. Quah BJ, O'Neill HC, (2005) The immunogenicity of dendritic cell-derived exosomes. Blood Cells Mol Dis 35: 94-110.
35. Bhatnagar S, Shinagawa K, Castellino FJ, Schorey JS, (2007) Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. Blood 110: 3234-3244.
36. El-Attar HA, Kandil MH, El-Kerm YM, El-Ghandour MK, (2010) Comparison of serum survivin and alpha fetoprotein in Egyptian patients with hepatocellular carcinoma associated with hepatitis C viral infection. Asian Pac J Cancer Prev 11: 897-903.
37. Sugahara K, Uemura A, Harasawa H, Nagai H, Hirakata Y, et al. (2004) Clinical relevance of survivin as a biomarker in neoplasms, especially in adult T-cell leukemias and acute leukemias. Int J Hematol 80: 52-58.
38. Croswell JM, Kramer BS, Crawford ED, (2011) Screening for prostate cancer with PSA testing: current status and future directions. Oncology (Williston Park) 25: 452-460, 463.
39. Mazzola CR, Ghoneim T, Shariat SF, (2011) [Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer]. Prog Urol 21: 1-10.
40. Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, et al. (2008) Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 15: 80-88.
41. Clayton A, Turkes A, Navabi H, Mason MD, Tabi Z, (2005) Induction of heat shock proteins in B-cell exosomes. J Cell Sci 118: 3631-3638.
42. Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, et al. (2007) Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res 67: 2912-2915.
43. Fukuda S, Pelus LM, (2006) Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 5: 1087-1098.
44. Williams RM, Naz RK, (2010) Novel biomarkers and therapeutic targets for prostate cancer. Front Biosci (Schol Ed) 2: 677-684.
45. Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C, (2005) Exosomal like vesicles are present in human blood plasma. Int Immunol 17: 879-887.
46. Savina A, Furlan M, Vidal M, Colombo MI, (2003) Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem 278: 20083-20090.